VHB937, Placebo 00 mg/ 00mL, concentrate for solution for infusion (Placebo to VHB937)
CVHB937B12201
Phase 2 small_molecule active
Quick answer
VHB937, Placebo 00 mg/ 00mL, concentrate for solution for infusion (Placebo to VHB937) for Amyotrophic Lateral Sclerosis (ALS) is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Amyotrophic Lateral Sclerosis (ALS)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active